Compare · NVO vs RNA
NVO vs RNA
Side-by-side comparison of Novo Nordisk A/S (NVO) and Atrium Therapeutics Inc. (RNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 1284.9x RNA ($131.4M).
- Over the past year, NVO is down 30.8% and RNA is down 84.3% - NVO leads by 53.5 points.
- RNA has been more active in the news (12 items in the past 4 weeks vs 4 for NVO).
- Both have 25 recent analyst ratings on file.
- Company
- Novo Nordisk A/S
- Atrium Therapeutics Inc.
- Price
- $38.82-1.05%
- $7.68-1.60%
- Market cap
- $168.79B
- $131.4M
- 1M return
- -10.14%
- -19.49%
- 1Y return
- -30.77%
- -84.27%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 12
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Atrium Therapeutics Inc.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; and to design, engineer, and develop therapeutics that combine tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies to access previously undruggable tissue and cell types, and target underlying genetic drivers of diseases. In addition, it develops muscle programs, which focuses on the treatment of facioscapulohumeral muscular dystrophy, Duchenne muscular dystrophy, muscle atrophy, and Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is based in La Jolla, California.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
Latest RNA
- Amendment: SEC Form 8-K/A filed by Atrium Therapeutics Inc.
- SEC Form 8-K filed by Atrium Therapeutics Inc.
- Atrium Therapeutics Announces $50 Million Private Placement
- Chief Scientific Officer Younis Husam covered exercise/tax liability with 11,216 shares, decreasing direct ownership by 21% to 41,441 units (SEC Form 4) to cover taxes
- Chief Medical Officer Hughes Steven George covered exercise/tax liability with 21,459 shares, decreasing direct ownership by 29% to 51,638 units (SEC Form 4) to satisfy withholding tax
- Director Boyce Sarah covered exercise/tax liability with 126,418 shares, decreasing direct ownership by 48% to 138,668 units (SEC Form 4) (withholding obligation)
- Director Flanagan W. Michael covered exercise/tax liability with 22,812 shares, decreasing direct ownership by 42% to 31,974 units (SEC Form 4) to satisfy withholding tax
- Officer Kenney Stephanie covered exercise/tax liability with 2,375 shares, decreasing direct ownership by 7% to 33,085 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Winslow Brendan R. covered exercise/tax liability with 6,742 shares, decreasing direct ownership by 15% to 36,859 units (SEC Form 4) (for withholding tax)
- Officer Gallagher Kathleen P. covered exercise/tax liability with 11,632 shares, decreasing direct ownership by 9% to 119,729 units (SEC Form 4) (for tax liability)